The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Exploring an AI-guided screening approach for identifying patients at high risk of cardiac ATTR
Ilia Davarashvili, MD, Leumit Health Services and Leumit Start, Tel Aviv, Israel, shares insights into an artificial intelligence (AI)-guided screening approach that incorporates clinical, demographic, and echocardiographic parameters to identify patients at high risk for cardiac transthyretin amyloidosis (ATTR-CM). Dr Davarashvili highlights that, while the algorithm identified more cases than in the general screening population, AI should be combined with good clinical practice and cardiologist expertise. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
